Background: Bisulfite sequencing is widely employed to study the role of DNA methylation in disease; however, the data suffer from biases due to variability in depth of coverage. Imputation of methylation values at low-coverage sites may mitigate these biases while also identifying important genomic features and motifs associated with predictive power.
Background
Type 2 diabetes (T2D) is a complex disorder involving interactions between genetic and environmental factors acting in multiple tissues over time. Signatures of T2D are wellcharacterized and include impaired insulin production in pancreatic islets, insulin resistance in skeletal muscle, inflammation and dysregulation of lipid metabolism and endocrine signaling in adipose tissue, and significant contributions from liver, intestine, and brain. Although T2D risk factors such as lifestyle and genetic variants have been identified, the mechanisms by which these factors interact to cause T2D remain poorly understood.
Genome-wide association studies (GWAS) show that the majority of T2D-associated variants lie in non-coding regions of the genome [1] [2] [3] . These variants therefore lack a clear relationship with any potential causal genes, underscoring the importance of identifying the epigenetic mechanisms by which they could affect gene expression. Preliminary cis-eQTL studies have shown strong enrichment for regulatory variants among T2D GWAS loci in skeletal muscle [4] and islets [5, 6] ; however, the specific epigenetic mechanisms that mediate cis-genetic variant regulation of T2D-associated genes remain unclear.
DNA methylation is an epigenetic mark that is thought to integrate environmental signals with gene expression [7] [8] [9] and may contribute to regulation of T2D-associated genes [10] [11] [12] [13] . In mammals, DNA methylation occurs primarily on cytosines of CG dinucleotides (CpGs). The extent to which methylation plays a causal role in altering gene expression, however, remains debated [14] [15] [16] [17] [18] . There is experimental evidence that DNA methylation can prevent [19] [20] [21] or promote [22, 23] binding of some transcription factors (TFs) to particular binding sites (TFBS), supporting the hypothesis that methylation may directly affect TF affinity and therefore gene expression. However, there is also evidence that methylation of TFBS may occur after TF release rather than cause it [24] [25] [26] [27] [28] [29] [30] [31] . In this model, methylation is merely a byproduct of other epigenetic processes, serving as a means of crosstalk among other epigenetic factors such as nucleosomes and TFs that may act non-concurrently [21, [32] [33] [34] .
Nevertheless, methylation remains a crucial epigenetic mark to consider in the context of T2D. There is strong evidence that methylation is a mode for heritable transmission of epigenetic information, as it can be stably propagated through both mitosis and meiosis [35] [36] [37] [38] [39] . This transmission across cells could contribute to the maintenance of the T2D phenotype, particularly in T2D-associated tissues such as adipose, skeletal muscle, and pancreatic islets.
Most previous work to characterize the role of methylation in T2D has important design limitations, including suboptimal choice of tissue (blood) [40, 41] and reliance on arraybased assays [42] [43] [44] . Sparse genome-wide measurements of methylation such as the Illumina-450k array, and to a lesser extent the new Illumina Infinium MethylationEPIC (EPIC) array [45] , are biased towards gene and promoter regions, with relatively little coverage of intergenic regions where a large fraction of T2D GWAS loci are located. Despite this, headway has been made in identifying interesting differentially methylated genes in the T2D state. For example, T2D GWAS variants such as TCF7L2 and KCNQ1 have been shown to be differentially methylated in both adipose tissue [43, 46] and pancreatic islets [44] . A recent whole-genome bisulfite sequencing (WGBS) analysis of methylation in pancreatic islets in healthy and T2D individuals found that CTCF, FOXA2, and NEUROD1 transcription factor motif sites were enriched in differentially methylated regions in pancreatic islets [47] . Further whole-genome work is needed to characterize methylation patterns in adipose, skeletal muscle, pancreatic islets, and other T2D-relevant tissues.
WGBS is advantageous in that it provides unbiased coverage of most of the ~28 million CpGs in the genome. However, quantitative methylation estimates from CpGs sequenced at low depth are subject to error and are typically removed before performing downstream analysis [48] , which can lead to the exclusion of millions of CpGs in any given data set. Furthermore, due to the high cost and sample input requirements of WGBS, it is often infeasible to generate deep-coverage data for a large number of replicates.
One potential remedy for these inefficiencies is the generation of a small number of high-coverage reference samples in relevant tissues and disease states. These reference samples could be used to facilitate lower coverage and/or lower density methylation profiling in a larger number of samples. Such techniques have already been used to increase the power of GWAS studies by leveraging data from sparse yet costeffective SNP arrays [49] [50] [51] .
Machine and deep learning algorithms have shown promise in providing accurate methylation estimates after training on sparse data sets [52, 53] . Prediction accuracy, however, is still far from the currently expected SNP imputation accuracy in GWAS [52] , leading to the need for algorithm improvement. The most recent methylation imputation methods used either random forest [54] or deep neural network [55] algorithms. A relatively new algorithm called extreme gradient boosting (XGBoost) has been shown to outperform both methods in accuracy and computational efficiency in data science competitions when highly predictive features can be constructed [56] . Previous imputation methods have also only classified CpG sites as fully unmethylated or methylated. This binarization of the data not only represents a loss of information but also ignores the possible significance of intermediate methylation levels as a conserved genomic signature [57] . Furthermore, although previous algorithms have constructed features that capture the local correlation structure of CpGs [52, 58] as well as information from the surrounding DNA sequence context [52, 53, [59] [60] [61] , no algorithms have created features that incorporate information from multiple samples in the same tissue and/or disease state. This adaptation could improve prediction for CpGs that are not highly correlated to neighboring CpGs or strongly associated with their surrounding DNA context. Importantly, machine and deep learning algorithms not only can impute missing values in sparse methylation data sets, but can also identify genomic features and sequence motifs associated with methylation patterns in different tissues [52, 53, 59, [62] [63] [64] . For example, a previous random forest [52] algorithm identified TFBS including ELF1, MAZ, MXI1, and RUNX3 to be predictive of methylation levels in whole blood. A recent deep learning algorithm [53] found that transcription factor motifs such as Foxa2 and Srf, which are both implicated in cell differentiation and embryonic development, were important to methylation prediction in mouse embryonic stem cells. These algorithms are therefore useful for characterizing methylation regulatory networks, but they have not yet been applied to study methylation in T2D-implicated tissues such as adipose, skeletal muscle, and pancreatic islets.
In this work, we generated EPIC and WGBS data on 58 human samples from adipose, skeletal muscle, and pancreatic islets. Samples from adipose and skeletal muscle included those from patients with normal glucose tolerance (NGT) and T2D. We found 1) a high rate of missingness in the WGBS data and 2) discordance between WGBS and EPIC, biased towards low coverage and intermediate methylation sites. Therefore, we developed an imputation method based on XGBoost called BoostMe, which is designed to leverage information from multiple samples in the same tissue and disease state to impute low-coverage CpGs in WGBS data. We find that, for all tissues and all genomic contexts, BoostMe outperforms other methods, achieving the lowest error as well as the highest computational efficiency. We also examine the effect of imputation on WGBS accuracy by comparing raw WGBS and imputed methylation values to those of the EPIC array. We find that discordance between EPIC and WGBS measurements at low WGBS depth is mitigated after imputation using BoostMe, supporting the use of imputation as a preprocessing step for WGBS data pipelines. Finally, we compare the ability of BoostMe and DeepCpG, a deep learning method, to identify biologically interesting features and sequence motifs for each tissue. We find that, while BoostMe identifies features important to general methylation levels across tissues, DeepCpG also discovers differences in sequence motifs associated with methylation between tissues. However, neither algorithm readily identifies differences between NGT and T2D tissues. Our findings demonstrate the current power and limitations of machine and deep learning algorithms to both improve the quality of, and infer biological meaning from, genome-wide DNA methylation data.
Results

BoostMe outperforms random forests and DeepCpG for methylation imputation
To address the high rate of missingness spread across the genome in our WGBS data (Figure 1 , Additional file 1: Figure S1 , S2), we developed BoostMe, a method for imputing methylation values using WGBS data from multiple samples. Previous attempts at DNA methylation imputation based on penalized functional regression [61] , random forests [52] , and deep neural networks [53] yielded relatively poor predictive accuracy genome-wide (RMSE > 0.23, AUROC < 0.93) (Additional file 1: Table S1 ). To improve on those methods, we implemented predictive models optimized for WGBS data using both random forest and gradient boosting [56] algorithms. We constructed a total of 648 features designed to both parallel and improve upon previous work [52] . Prediction features constructed from the WGBS data included the nearest non-missing neighboring CpG methylation (beta) values upstream and downstream of the CpG of interest, base-pair distance to the neighboring CpGs, and the average methylation value of the CpG of interest in other samples from the same tissue and disease state. We also included features that describe the genomic context of individual CpGs such as histone marks (n=7), computational predictions of TFBS (n=608), chromatin states (n=13), and ATAC-Seq peaks (as a measure of DNA accessibility; see Methods, Additional file 1: Table S2 for a full list of features). Using these features, and after applying additional quality control exclusion criteria (Methods), the average number of CpGs usable for training and testing per sample was 20 million (range: 14.7 million -21.2 million), and the average number of missing CpGs able to be imputed per sample (sequencing depth < 10x) was 2.6 million (range: 750,000 -7.7 million) (Additional file 2).
We compared the performance of BoostMe with random forests and DeepCpG for predicting continuous methylation values in WGBS data from adipose NGT (n=12), adipose T2D (n=12), muscle NGT (n=12), muscle T2D (n=12), and pancreatic islet (n=10) tissue (Figure 2A) . We found that both BoostMe and random forests outperformed DeepCpG, achieving an average root-mean-squared error (RMSE) of 0.10, area under the receiver operating characteristic curve (AUROC) of 0.99, area under the precision-recall curve (AUPRC) of 0.99, and an accuracy of 0.96 ( Table 1) . Unlike previous methods [52, 53] , we trained on continuous methylation values rather than binary values because of the available depth in our WGBS data, and found that this change improved overall RMSE by at least 0.06 and performed similar for AUROC, AUPRC, and accuracy (Additional file 1: Table S3 ). To investigate whether BoostMe could produce accurate predictions for intermediate CpGs as well, we measured performance specifically at CpGs that had an average methylation value across samples between 0.20 and 0.80 inclusive. We found similar trends in algorithm performance, with both BoostMe and random forests having an RMSE of 0.13 and DeepCpG an RMSE of 0.23 ( Table 1) . We hypothesized that altering the training set distribution to include more CpGs with average methylation values in the intermediate range would improve prediction at these CpGs; however, performance did not improve significantly (Additional file 1: Figure S3 ).
To characterize performance patterns in different genomic contexts, we compared the performance of each algorithm within tissue-specific chromatin states ( Figure 2B) . Again, BoostMe and random forests outperformed DeepCpG in all chromatin states. In addition, all three algorithms exhibited the same trend across chromatin states, with the best predictive performance in TSS-associated states, which were strongly associated with low methylation levels (Additional file 1: Figure S4 ).
Finally, we benchmarked the computational performance of all algorithms. BoostMe had a training runtime that was up to 40x faster than random forests using identical computational resources and up to 400x faster than DeepCpG ( Table 1) . Both BoostMe and random forests training times outperformed DeepCpG, which took multiple days to train due to the need to train CpG and DNA modules separately before training the joint module (Methods).
Imputation reduces WGBS discordance with EPIC at low sequencing depth
To determine the effect of imputation on WGBS accuracy, we first characterized the concordance of WGBS and EPIC array methylation estimates at the same CpGs in the same samples ( Figure 3A) . We found that disagreement between the two platforms was concentrated at lower sequencing depth, with varying levels of discordance at high sequencing depth. Neither EPIC nor WGBS estimates can be considered the true methylation level of a particular CpG; however, since discordance between the two estimates was a function of sequencing depth, we hypothesized that discordance at low depth could be mostly attributed to WGBS inaccuracy, and discordance at high depth to EPIC inaccuracy.
Figure 3 | Imputation reduces discordance between WGBS and EPIC methylation estimates at low sequencing depth. (A)
Root-mean squared discordance (RMSD) between EPIC and WGBS methylation estimates at CpGs common between the two platforms. X-axis: depth at which the CpG was sequenced, binned into intervals of 5. Y-axis: the methylation (beta) value of the CpG as measured by the EPIC array, binned into intervals of 0.
Yellow color indicates higher discordance. (B) RMSD between EPIC and imputed WGBS values at the same CpGs as in A. (C) Difference between A and B.
We then used BoostMe to impute and replace CpGs common between the two platforms. We found that the discordance was mitigated (Figure 3B) , particularly at lower WGBS depth ( Figure 3C ). Furthermore, we found that discordance mitigation at lower WGBS depth was robust with respect to the EPIC array probe type examined (Additional file 1: Figure S5 ). Discordance at higher depth was variable and in some cases increased after imputation (Figure 3C ).
BoostMe and random forests identify features important to general methylation levels
To interrogate differences in the methylation patterns of the different tissues and disease states, we examined the top variable importance scores output by random forests and BoostMe (Figure 4 , Additional file 1: Figures S6, S7 ). Both algorithms highly prioritized the sample average and neighboring CpG features, which were wellcorrelated with the methylation value of the CpG of interest. To further characterize CpG-neighbor correlation, we measured the extent to which neighboring CpGs differed in methylation profile from the CpG of interest. We found that the difference was generally small (< 0.2) when the neighbors were within 50bp, but that a small fraction of CpG-neighbor pairs within this distance differed drastically (> 0.9) (Additional file 1: Figure S8 ).
We found that random forests ranked highly features that were negatively correlated with methylation values, especially those associated with open chromatin and promoter regions such as H3K4me3, ATAC-Seq peaks, CpG islands, and the TSS-related chromatin states ( Figure 4A ). Random forests also identified several methylationassociated transcription factors such as YY1, REST, and EP300. In concordance with previous results [52] , we found that random forests were biased to rank highly features that are positively correlated with each other. This trend was particularly evident in the In contrast, BoostMe did not exhibit the same bias in favor of positively correlated features ( Figure 4B ). Since gradient boosting trees are trained sequentially, with each subsequent tree designed to reduce error from the previous tree, BoostMe is less likely to rank highly features that exhibit strong positive cross-correlations. Therefore, BoostMe more highly prioritized chromatin states that were positively correlated with methylation such as "Quiescent/low signal" and "Weak transcription" in addition to highly predictive features that were negatively correlated with methylation identified by random forests, such as ATAC-Seq peaks and H3K4me3. BoostMe did not report as many methylation-associated transcription factors as highly predictive, likely because of their high positive correlations with each other and with other features indicative of open chromatin, such as ATAC-Seq peaks and H3K4me3.
To further determine whether BoostMe or random forests could identify features that were important to specific tissues, we trained models using only transcription factor binding sites in tissue-specific regions of open chromatin. We found that the rankings were generally the same across tissues for both algorithms (Additional file 1: Tables  S3, S4 ).
DeepCpG identifies sequence motifs important to general and tissue-specific methylation values
We examined the sequences that maximally activated filters from the first convolutional layer of the top-performing DNA modules from DeepCpG as described in Angermueller [53] . We found that motif discovery using DeepCpG was inherently noisy, such that two networks trained on the same data could report slightly different motifs, or the most significantly matching TF to a particular motif could vary. To account for this noise, we measured the reproducibility of each TF discovery by training ten DNA models with identical architectures for each tissue and disease state combination (Figure 5) . In our analysis, we consider only known TF motifs that were found in at least half of trained DNA modules. For a full, unfiltered list of TFs identified and corresponding motif logos, see Additional file 3.
Figure 5 | Reproducible motifs identified by DeepCpG DNA models in different tissues and disease states.
Known sequence motifs discovered for each tissue and disease state are plotted by (x-axis) the average q-value* of the motif across all DNA models it was discovered in and (y-axis) the total number of models the motif was identified in. *q-value is the p-value indicating the significance of similarity between the learned motif and the ENCODE [71] database match, corrected for false discovery rate.
Similar to BoostMe and random forests, DeepCpG learned sequence motifs important to methylation prediction across multiple tissues and disease states. For example, SP1, which was reproducible in adipose and muscle, has a GC-rich motif, is often associated with promoters of housekeeping genes, and is known to protect CpG islands from de novo methylation [24, 65] . ZNF281 (ZBP-99), also discovered in adipose and muscle, binds GC-rich promoters, and may play important roles in regulating cell proliferation, differentiation, and oncogenesis [66, 67] . CTCF, identified in four of the five tissues, is a multifunctional regulator of gene expression [68, 69] , and its binding may be influenced by differential methylation [70] . The majority of all reproducible known motifs had a negative correlation with methylation values (Figure 6 ).
Figure 6 | Heat map of correlations between reproducible motifs and methylation values.
Correlations were calculated as the Pearson's correlation coefficient between the weighted activations of
Motif Correlation with Methylation
each motif from the first convolutional layer and the WGBS methylation value of CpGs (Methods). Motifs are labeled with their corresponding sequence logo representation of the learned DeepCpG DNA model filter. Hierarchical clustering shows that motifs fall into two major categories: GC-rich and negatively correlated with methylation, and less GC-rich and positively correlated with methylation.
Unlike BoostMe and random forests, DeepCpG was also able to learn motifs that are known to play key regulatory roles in their respective tissues based on previous biological findings. For example, EBF1 was highly reproducible in both adipose tissues, and is known to be an adipocyte-expressed transcription factor that regulates adipocyte morphology and lipolysis [72, 73] . ASCL2, which may inhibit myogenesis by antagonizing myogenic regulatory factors [74] , was identified in both muscle tissues. The same filter also matched with MYOD, which is considered the master regulator of myogenesis [75, 76] . Finally, in pancreatic islets, DeepCpG identified FOXA1, which plays a role in maintaining the metabolic and secretory features of beta cells [77, 78] . The same filter also matched significantly to FOXA2, which is required for the differentiation of pancreatic alpha cells and controls PDX1 gene expression in pancreatic beta cells [78, 79] . DeepCpG also identified TCF12, which is involved in pancreatic development [81, 82] , and NRF1, which plays a role in beta cell insulin secretion and glucose metabolism [83, 84] .
We also detected reproducible differences in motifs between NGT and T2D. For example, PITX2, a key regulator of skeletal myogenesis [85, 86] , was highly reproducible in Muscle NGT and absent in Muscle T2D (Figure 5) . However, neither PITX2 nor any other motifs showed significant differences in their correlation with methylation between the NGT and T2D states (Figure 6 ).
Discussion
To better understand the extent to which DNA methylation regulates tissue-specific gene expression, and the specific contribution of methylation dysregulation to T2D etiology, we generated WGBS and EPIC data from 58 samples of human adipose, skeletal muscle, and pancreatic islets. We discovered that, despite the relatively deep mean sequence coverage in these samples (~40x), our ability to interpret these data was limited by a relatively high rate of missingness (Figure 1 , Additional file 1: Figure  S1 , S2) and by significant bias in the level of discordance between methylation estimates from WGBS versus the EPIC array (Figure 3) . To address these limitations, we developed BoostMe, an imputation method for WGBS that improves upon previous algorithms by (1) using a gradient boosting algorithm based on XGBoost [56] , (2) leveraging a new sample average feature, and (3) training on and predicting continuous methylation values. BoostMe outperformed both random forests and DeepCpG in computational efficiency while achieving similar accuracy to random forests across tissues and chromatin states (Figure 2, Table 1 ).
Since 70-80% of CpGs in the genome are invariantly methylated across tissues and samples [48, 87] , it is no surprise that most of the gains in accuracy came from using the sample average feature. For this reason, we also benchmarked all algorithms on intermediate CpG methylation values, which are more likely to be biologically significant and vary across tissues and samples. Both tree-based algorithms still had lower RMSE than DeepCpG (Additional file 1: Table S3 ), despite DeepCpG being designed to detect sample-specific differences. However, DeepCpG was also originally optimized for single-cell bisulfite sequencing, not WGBS. Thus, we expect that a deep neural architecture designed specifically for WGBS data would perform better and will explore such developments in a future work.
To assess the effect of imputation on the quality of WGBS data, we compared WGBS and imputed methylation estimates from BoostMe to EPIC data from the same samples. Interestingly, we find that imputation mitigates discordance between WGBS and EPIC estimates of the same CpGs, particularly at low coverage sites (Figure 3) . This result suggests an improvement in the quality of WGBS estimates, making BoostMe a potentially beneficial preprocessing step for WGBS data pipelines. However, we did not attempt to validate that this result holds for non-EPIC sites.
One limitation of BoostMe is that, like previous methodology [52, 53] , it relies heavily on the locally correlated structure of neighboring CpGs to identify sample-specific differences. Average methylation haplotype blocks, defined as consecutive CpGs with methylation correlation of r 2 > 0.5, measure just 95 bp long on average [88] . To achieve the goal of highly accurate methylation imputation from sparse data, further work must be done to develop methodology that can detect sample-specific differences without depending as heavily on neighboring CpGs. For example, the DNA module of DeepCpG, which uses only DNA sequence to predict methylation levels, could be improved to achieve higher accuracy in CpG-sparse regions, eliminating the need for dense CpG input.
We also investigated the ability of all algorithms to identify differences in features important to methylation across tissues and disease states. We found that the variable importance score rankings output by BoostMe and random forests do not readily identify tissue-or disease-specific features. Instead, both algorithms rank highly features important to general methylation levels such as ATAC-Seq peaks and other measures of open chromatin, which are negatively correlated with methylation values, as well as features associated with inaccessible chromatin, which are positively correlated with methylation values (Figure 4) .
Consistent with previous experimental findings, random forests identified methylationsensitive TFs such as YY1, REST, and EP300 [30, [89] [90] [91] [92] . However, many of the features identified by random forests were also positively correlated with each other (Figure 4) , which is a known bias of random forests [52, 93] . Although there are existing methods to correct for this bias such as conditional random forests [93] , they scale poorly to large data sets with hundreds of variables. BoostMe does not have the same bias to highly rank positively correlated features, but it also does not specifically correct for the correlation when it calculates variable importance [56] . Instead, BoostMe highly ranks just one feature from a group of positively correlated features, making it unclear which feature or features are actually important.
DeepCpG, on the other hand, learned important sequence motifs in different tissues related to methylation prediction without any feature construction (Figure 5) , thus representing an unbiased approach to characterizing methylation regulatory networks. DeepCpG learned common motifs such as SP1, ZNF281, and CTCF, which have roles in cell differentiation and development [24, [65] [66] [67] [68] [69] [70] . This result reinforces the previously known importance of methylation in these biological processes and validates the ability of DeepCpG to identify motifs that are specifically associated with methylation. DeepCpG also identified important tissue-associated motifs such as EBF1 in adipose, ASCL2 in muscle, and FOXA1, TCF12, and NRF1 in pancreatic islets, which have also been shown to be involved in regulating differentiation and development in their respective cell types [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] .
To see whether BoostMe or random forests could reproduce the same findings as DeepCpG, we trained both algorithms using only TFBS. Neither algorithm identified notable differences among the tissues and disease states (Additional file 1: Tables  S4, S5 ). Therefore, despite outperforming DeepCpG in methylation prediction RMSE and speed, neither BoostMe nor random forests are ideal algorithms for learning differences in methylation regulation among tissues.
With DeepCpG, we were able to identify interesting candidates for methylation regulatory networks in different tissues supported by previous experimental results. This result highlights the promise of supervised deep learning methods to identify biological signatures in genome-wide data. However, these results are limited by the noise in DeepCpG outputs due to motif similarity and stochasticity in the model training process. We attempted to address this limitation by training multiple DNA models with identical architectures on each tissue and disease state combination (Figure 5 ), however, it is possible that all motifs identified by all networks have the potential to be significant, not just those that are reproducible.
We attempted to identify significant differences between the NGT and T2D states using motif correlation with methylation ( Figure 6 ). Using this measure, we found no differences between the NGT and T2D adipose and muscle. However, the correlation does not take into account the complex, non-linear relationships learned by the deep neural network during training. Understanding these relationships is an active area of research. It is possible that there are reasons why DeepCpG identified motifs reproducible in NGT but not T2D, but that these reasons cannot be interrogated with correlation alone. Due to these limitations, important questions such as the extent to which methylation plays a causal role in altering gene expression cannot be answered from our results. Additional experimental and computational work must be done to understand the mechanisms by which these TFs influence methylation and the T2D state.
Methods
Sample collection
Muscle and adipose NGT and T2D samples were collected as previously described [4] . Briefly, we attempted to contact participants and participants' relatives from previous diabetes-related studies [94] [95] [96] [97] and also recruited subjects by newspaper advertisements. We excluded individuals with any diseases or drug treatments that might confound analyses. We defined glucose tolerance categories of NGT and T2D using World Health Organization (WHO) criteria [98] . Biopsies were performed by 9 experienced and well-trained physicians from 2009-2013 in 3 different study sites (Helsinki, Kuopio, and Savitaipale). The study was approved by the coordinating ethics committee of the Hospital District of Helsinki and Uusimaa. A written informed consent was obtained from all subjects.
Islet samples were collected as previously described [5] . Briefly, samples were procured from the Integrated Islet Distribution Program, the National Disease Research Interchange (NDRI), or ProdoLabs. Islets were shipped overnight from distribution centers, prewarmed in shipping media for 1-2 h before harvest, and cultured in tissue culture-treated flasks. Genomic DNA was then isolated from islet explant cultures and used for sequencing. 
Whole-genome sequencing
WGS data processing
Raw FASTQ files were evaluated with FastQC [99] . Adapter sequences were trimmed using Atropos [100] , and reads with at least one pair shorter than 25 bp were excluded. Reads were aligned to the reference genome (GRCh37) using BWA MEM [101] , followed by Samblaster [102] for marking duplicates.
WGS variant calling
SNPs and indels were called separately for all sample BAM files using GATK HaplotypeCaller [103] . Variants were filtered using GATK Variant Quality Score Recalibration. Quality score cutoffs were chosen by comparing rates of discordance with SNP array genotypes.
WGBS data processing
Raw FASTQ were pre-processed as above and aligned using bwa-meth [104] . Methylation values were extracted using the MethylDackel 'extract' command, including bias correct based on the values recommended by the 'mbias' command, and forwardand reverse-strand CpGs were merged with a minimum coverage cutoff of 10 (https://github.com/dpryan79/methyldackel). Methylation level data from the X and Y chromosomes were excluded.
EPIC Array Data Processing
The EPIC data are part of a much larger, unpublished study. As such, all samples were processed jointly with other samples from the larger study. We processed raw signal idat files using minfi v1.20.2 [105] with the Illumina normalization method. We analyzed the quality of each sample looking for outliers across a variety of measures including fraction of failed probes (detection p-value $>$ 0.05), median methylated and unmethylated intensity, control probe signal (using the returnControlStat function from shinyMethyl v1.10.0 [106] ), distribution of the overall methylation profile, and principle component analysis. None of the WGBS included in this study were flagged as outliers.
In addition, we verified the identity of each sample by comparing genotypes assayed on the EPIC array to imputed genotypes using the HRC reference panel r1.1 [107] and Illumina Omni2.5 array genotypes.
For both the earlier 450k and recent EPIC Illumina methylation array, previous studies [108] [109] [110] [111] have identified poor quality probes that either do not uniquely map to the reference genome or contain common genetic variation. These properties make the signal at these probes un-reliable. We removed such probes from the EPIC array. First, we removed cross-reactive probes on the EPIC chip by mapped non-control probes back to the entire bisulfite-converted genome, using Novoalign's -b4 option, with allowance for up to three mismatches in the probe alignment (-R120 option). We kept only unique mapping probes. Second, we removed probes with a SNP within 10 bp of the 3' end of the probe, within the target CpG itself, and finally, in the case of type I probes, if the variant overlaps the single base extension site. We used 10 bp as this cutoff is consistent with previous studies [109] . For SNPs we used common (MAF ³ 1%) SNPs, indels or structural variation in the phase 3 1000 Genomes European dataset, common (MAF ³ 1%) SNPs in the HRC reference panel r1.1, and SNPs appearing at all our own samples, even at low frequency, after imputation to the HRC reference panel.
As a final step, we combined our blacklist with a previously published blacklist [111] for a total of 120,627 probes which were removed from analysis. In addition, we removed probes per tissue with a high detection p-value (p-value > 0.05 in ³ 5% of samples from the larger study). After blacklist filters, we removed 578 adipose probes, 733 muscle probes, and 2,206 islet probes based on the per sample filters.
Feature construction for BoostMe and random forests
We used the same 648 features in the BoostMe and random forest algorithms (see Additional file 1: Table S2 for a detailed list). Prior to feature construction, we applied a further set of exclusion criteria to filter the CpGs included in training, validation, and testing. Only autosomal CpGs were used (n=25,586,776). We overlapped WGS data with the WGBS data from all samples and excluded CpGs for which the CG dinucleotide on either strand was disturbed by a SNP or indel that was 2 bp long. We also excluded all CpGs located in ENCODE blacklist regions [112] .
CpG features
Features constructed from the WGBS data included neighboring CpG methylation values and the sample average feature. Neighboring CpG methylation values were taken within the sample of interest. For each neighbor, the methylation value as well as the base-pair distance from the neighbor to the CpG of interest were included as features. The sample average feature was created by taking the average of all samples within each tissue at the CpG of interest, not including the sample being interrogated. Samples in which the CpG was not sequenced above 10x coverage were excluded from the calculation. CpGs without a measurement above 10x coverage from at least two additional samples were also excluded.
Genomic features
We constructed both general and tissue-specific genomic features. General genomic features were the same across all tissues and included GC content, recombination rate, GENCODE annotations, and CpG island (CGI) information. GC content data was downloaded from the raw data used to encode the gc5Base track on hg19 from the UCSC Genome Browser [113, 114] . DNA recombination rate annotations from HapMap were downloaded from the UCSC hg19 annotation database (http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/). CpG island coordinates were obtained from UCSC browser. CpG island shores and shelves were calculated from CpG island coordinates by taking 2 kb flanking regions. GENCODE v25 transcript annotations were downloaded from the GENCODE data portal (ftp://ftp.sanger.ac.uk/pub/gencode/Gencode_human/release_25).
Tissue-specific genomic features included ATAC-seq, chromatin states, histone marks, and transcription factor binding sites (TFBS). These features were all binary, with 0 indicating that the CpG of interest did not overlap that feature, and 1 indicating overlap. Chromatin state annotations were obtained from a previously published 13 chromatin state models for 31 diverse tissues that included islets, skeletal muscle, and adipose [5] . This model was generated from cell/tissue ChIP-seq data for H3K27ac, H3K27me3, H3K36me3, H3K4me1, and H3K4me3, and input from a diverse set of publicly available data [115] [116] [117] [118] . ATAC-seq data was obtained from previously published studies for islets [5] , skeletal muscle [4] , and adipose [87] . TFBS data was obtained as described in [4] , with additional PWMs from [119] . TFBS data was filtered for each tissue by the ATAC-seq feature to only include hits overlapping an ATAC-seq peak. We merged hits from multiple motifs of the same transcription factor to reduce the number of variables included in the algorithm and optimize computational efficiency.
BoostMe and random forests implementation
For BoostMe we used the xgboost package (version 0.6-4) [56] in R [120] (version 3.3.1). Hyperparameters were tuned using a random search with the tuneParams function in the mlr package [121] , however we found that performance did not improve significantly over the default settings of the xgb.train function in the xgboost package.
For random forests we used the ranger package (version 0.6.0) in R, which facilitates random forest training and testing on multiple CPUs [122] . In the final algorithm, we set num_trees to 500 to balance computational time and accuracy, and used default values for other parameters after finding that performance was robust to different settings.
For both algorithms, we used regression trees to predict a continuous methylation value between 0 and 1 for CpGs of interest. Algorithms were trained on individual samples within each tissue and disease state combination. We trained only on CpGs with at least 10x coverage and no more than 80x coverage. Random forest variable importance was calculated using the mean decrease in variance at each split as implemented in the ranger package. BoostMe variable importance was evaluated for each variable as the loss reduction after each split using that variable as implemented in the xgboost package.
Due to memory limits, algorithms were trained on a random sample of 1,000,000 CpGs from all available CpGs within a sample, validated on a hold-out set of 500,000 CpGs, and benchmarked on another hold-out set of 500,000 CpGs. To account for possible biases that would arise from only training on a small subset of the over 20 million CpGs available for training from each sample, we repeated the process of randomly sampling CpGs for training, validation, and testing ten times for each sample using ten different random seeds and averaged the results.
Importantly, including all features was detrimental to the performance of the random forest algorithm. This effect was observed to a much lesser extent in BoostMe because trees are grown sequentially to fit the error of the previous tree, allowing BoostMe to ignore less-predictive variables more easily than the bootstrap aggregating algorithm used by random forest [56] . Therefore, to determine the combination of features for both algorithms, we added features in a stepwise fashion and compared the RMSE of each combination (Additional file 2). The best performance was achieved when we included the sample average feature, neighboring CpG values and distances, histone marks, and recombination rate; we used this abbreviated algorithm to benchmark performance. For the purpose of identifying interesting features (Figure 4) , all features were included.
WGBS methylation values follow a bimodal distribution, with the vast majority of CpGs being fully methylated or unmethylated. To see if we could improve prediction estimates at intermediate CpGs, we altered the sampling distribution to be more uniform instead of bimodal, randomly drawing an equal number of CpGs from each methylation bin for training (Additional file 1: Figure S3 ). We found no significant improvements in prediction.
DeepCpG implementation
Model training and testing
We implemented DeepCpG (version 1.0.4) as described in Angermueller et al. (2017) [53] . Briefly, for each of the five tissue and T2D status combinations (adipose NGT, adipose T2D, muscle NGT, muscle T2D, and islet) the data was first divided by chromosome into training (chr. 1, 3, 5, 7, 9, 11, 13, 15) , validation (chr. 16, 17, 18, 19, 20, 21, 22) , and test sets, corresponding to a rough 40-20-40 split. The DNA module and CpG module were trained on separate NVIDIA Tesla K80 GPUs and the performance of each module was evaluated individually on the test set. The joint module was trained with the best-performing DNA and CpG modules, and its predictions were used for final benchmarking. In contrast to original single-cell bisulfite implementation of DeepCpG which was trained and tested on binary methylation values, we trained and tested on continuous methylation values to parallel our implementation of BoostMe and random forests. We find that this change made no difference in the accuracy of the model (Additional file 1: Table S3 ).
We experimented with six different hyperparameter combinations for each DNA model, including three architectures (CnnL2h128, CnnL2h256, CnnL3h256) and two dropout rates (0, 0.2). We then selected the best-performing combination based on AUC (Additional file 2) and reported the motifs significantly matching the filters from the first convolutional layer of that model [123] . Similarly, we tested both RnnL1 and RnnL2 for the CpG model for each tissue. For the joint module, we tested JointL1h512, JointL2h512, and JointL3h512. The best-performing joint model was selected to evaluate RMSE, AUC, AUPRC, and accuracy for each tissue. We used a default learning rate of 0.001 for all models. For a detailed explanation of all model architectures, see http://deepcpg.readthedocs.io/.
Motif reproducibility and importance quantification
Filters of the first convolutional layer from the DNA module were visualized as described previously [53] . Briefly, selected sequence windows were aligned and visualized as sequence motifs using WebLogo [124] version 3.4. Discovered motifs were matched to annotated motifs in the Homo sapiens CIS-BP database using Tomtom 4.11.1 from both the MEME Suite [125] , which is the default for DeepCpG, and the ENCODE [71] database. In the final results, we used only the ENCODE matches to parallel our use of ENCODE TFBS for the random forest and BoostMe algorithms. Matches at FDR < 0.05 were considered significant. For consistency, we reported only the most significant motif match for each filter, however in some cases multiple motifs matched significantly to a single filter due to sequence similarity. For a complete list of significantly-matching motifs and sequence logos see Additional file 3.
Motif importance was quantified using the Pearson correlation coefficient with methylation values as previously described [53] . Briefly, we used DeepCpG to extract the activations of each filter from the first convolutional layer. We then averaged these activities across the 1,001bp window centered at the CpG of interest for a sample of 50,000 CpGs. The mean activations were then weighted by a linear weighting function that assigns the highest relative weight to the center position. We then calculated the Pearson correlation between the mean activations and the actual methylation value as measured by WGBS. CpGs lying in CpG islands were excluded from this analysis.
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Figure S1: Distribution of WGBS missingness across chromatin states, not normalized for total number of CpGs in that chromatin state. The proportion of total missingness was calculated for each tissue as the number of missing CpGs (sequencing depth < 10x) in that chromatin state divided by the total number of missing CpGs in that tissue. FOXN1  FOXN1  XBP1  SP1  TBX5  NFY  ZNF524  IRF4  GMEB2  NFIC  HOMEZ  RUNX3  TFCP2  TBX1  GMEB2  XBP1  TATA  RUNX2  TFCP2  SMC3  VDR  NFIC  NFY  HOMEZ  RUNX2  PAX3  PAX3  NFATC1  FOXN1  SPDEF  PTF1A  BCL6B  HOMEZ  HMX3  HNF4  ZNF524  AHR  ZNF713  BCL6B  BARHL2  GRHL1  VDR  PAX3  RUNX2  TCF12  ZNF713  HOMEZ  FOXN1  NFATC1  GLI  MYBL2  CEBPB  FOXK1  NHLH1  FOXN1  FOXC1  PTF1A  TBX20  TATA  NFY  IKZF2  TBX5  SOX9  NFY  TBX4  TATA  GRHL1  TATA  SOX10  FOXC1  NFKB  RUNX2  RHOXF1  TEAD1  TATA  HMGN3  ZNF713  THAP1  MYBL2  BARHL1  ESRRA  FOXJ3  AHR  VDR  PTF1A  CEBPB  ZNF143  ZBTB33  RHOXF1  SP1  HOXA13  IKZF2  SP1  TP53  HDAC2  TBX5  ZBTB14  FOXC1  ZNF282  IKZF2  TFCP2  HMGN3  BARHL1  NFKB  ZNF713  ZBTB14  HOXA13  MNT  ZNF713  CENPB  BCL6B  MYC  OTX1  ZBTB33  HMGN3  AHR  BCL  HEY1  BARHL2  GRHL1  MYC  TFCP2  NFKB  AHR  NFKB  ZNF143  CACBP  BCL6B  TBX20  PAX3  CACBP  BARHL2  TEAD1  ARHGEF12  HIC1  BCL  ESRRA  HOXA5  SIX5  ZSCAN4  HDAC2  FOXC1  ZNF282  BPTF  CHD2  TBX1  NFKB  BARHL2  IKZF2  XBP1  ZNF282  HDAC2  AIRE  PAX3  RUNX3  CENPB  ZNF282  TP53  THAP1  NANOG  ARHGEF12  NFAT  PTF1A  MEIS1  POU2F2  SP1  SOX4  NHLH1  ZBTB6  INSM1  RUNX2  MNT  BPTF  PRDM1  SP8  TBX4  HIC2  VDR  OTX1  NFAT  NFAT  ARHGEF12  TFAP4  GRHL1  MYC  HIC2  TP53  SIX5  PTF1A  ZNF524  ZSCAN4  PRDM1  RARA  FOXA  AHR  FOXK1  NHLH1  RBPJ  RORA  BCL6B  BARHL2  RHOXF1  ZNF524  CHD2  SREBP  HOXC12  ZSCAN4  ARHGEF12  FOXC1  ZNF384  ZBTB7A  CENPB  IKZF2  AIRE  VDR  ZNF384  ZNF384  HDAC2  HOXA5  TCF3  PRDM1  ZBTB6  NFAT  NFAT  TCF4  PROX1  BARHL1  ZNF384  RARG  ARHGEF12  ZBTB6  HIF1A  FOXG1  HIC1  SPI1  SP2  ESRRG  SOX8  ZNF524  PROX1  MNT  GLI  GRHL1  HOXA13  MAF  SP8  HOXC12  HIC1  ZBTB7A  ZNF282  NHLH1  BPTF  EBF1  TFAP4  NRF1  THAP1  ZKSCAN3  HOXA13  FOXG1  ZBTB7A  BPTF  SP2  CCDC6  CRX  CCDC6  ELF1  TBX4  NKX2-8  RUNX3  TFCP2  SIX5  HSF2  ESRRG  PROX1  BCL  HIF1A  PROX1  HMGN3  SOX9  RFX7  FOXJ3  TBX1  SOX10  HOXA11  TP53  SOX4  ELF1  ZBTB12  PAX6  ZBTB3  TP53  ZBTB7A  GZF1  BHLHE40  HNF1  TCF12  TCF12  ZBTB14  TCF12  SMC3  SMC3  SMC3  SMC3  SMC3  TCF12  ZIC3  ZIC3  RFX5  RFX5  ZIC3  HDAC2  HDAC2  NFIC  HDAC2  HDAC2  NFKB  NFKB  HDAC2  NFIC  NFKB  NHLH1  NHLH1  GATA  GATA  NHLH1  ZBTB7A  ZBTB7A  NFKB  NHLH1  ZBTB7A  VDR  VDR  NHLH1  NFKB  VDR  NFIC  NFIC  MAF  MAF  NFIC  RFX5  RFX5  ZBTB7A  ZBTB7A  RFX5  SP4  GATA  ZIC3  VDR  GATA  GATA  SP4  VDR  ZIC3  SP4  ZIC1  ZIC1  PBX3  PBX3  MAF  PBX3  PBX3  SP4  SP4  ZIC1  RUNX3  RUNX3  MYB  MYB  PBX3  MAF  MAF  RUNX3  RUNX3  MTF1  EGR3  EGR3  TFCP2  TFCP2  RUNX3  TFCP2  TFCP2  ZIC1  HSF  EGR3  WT1  WT1  AHR  EGR3  TFCP2  MYB  MYB  HSF  ZIC1  MYB  MTF1  MTF1  EGR3  RUNX2  WT1  RUNX2  RUNX2  RUNX2  AHR  TCF3  AHR  AHR  SP2  TCF3  ZFX  HF1H3B  TCF3  TCF3  MTF1  HF1H3B  TCF3  HSF  MTF1  SPDEF  TP53  HSF  HF1H3B  SPDEF  TP53  TFAP4  EGR4  EGR4  TFAP4  SP2  AHR  SP2  SP2  WT1  WT1  RUNX2  ZFX  TP53  TP53  TFAP4  SP2  SPDEF  ZFX  PAX2  PAX2  TFAP2B  TFAP2B  TFAP2B  EGR4  EGR4  SPDEF  TP53  SPDEF  MEF2  MEF2  SPZ1  TFAP4  TFAP4  CUX1  HF1H3B  EGR4  ZIC4  SPZ1  SMAD3  SMAD3  NR1H  SPZ1  ZIC4  HF1H3B  CEBPB  PLAG1  NR1H  ZNF219  SREBP  CUX1  ZIC4  ZNF219  NR1H  TFAP2B  NR1H  ZNF219  PAX2  PAX2  NR1H  MYBL1  HSF  RREB1  RREB1  ZFX  RARA  RREB1  ZNF281  ZNF281  RARG  ZFX  PAX2  GLI2  PLAG1  RARA  TFAP2B  PPARA  PLAG1  GLI2  RREB1  SREBP  ZBTB3  SREBP  PPARA  MYBL1  RARG  GLI2  PPARA  SREBP  SPZ1  THAP1  NANOG  THAP1  NANOG  CEBPB  ZNF281  SREBP  PLAGL1  TEAD2  THAP1  SPZ1  PLAGL1  TEAD2  THAP1  ZIC4  ZIC4  CACD  KLF4  PLAGL1  PAX6  RREB1  ZNF281  SMAD3  RARA  XBP1  XBP1  MYOD1  ZBTB3  KLF4  GLI2  PPARA  KLF12  CEBPB  ZNF524  ZNF281  PAX6  THAP1  NANOG  ZBTB3  PAX3  GMEB2  TEAD2  RARA  CEBPB  MYBL2  GLI2  RARA  ZNF524  CACD  PPARA  ZNF219  NR2C2  CACD  PATZ1  GFI1  RFX3  SMAD3  PATZ1  NR2C2  TBX20  TBX20  GCM1  RARG  SMAD3  MYOD1  MYOD1  PATZ1  KLF12  KLF12  KLF4  NANOG  PAX6  KLF7  KLF7  GMEB2  GFI1  ELF2 
